4 news items
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
KZIA
23 May 24
, Australia.
Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
KZIA
1 May 24
investigators
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
KZIA
21 Mar 24
in Sydney, Australia.
Our lead program is paxalisib, an investigational brain-penetrant inhibitor
Kazia announces presentation of new data at AACR Annual Meeting
KZIA
13 Mar 24
.
Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed
- Prev
- 1
- Next